Philippe Lucarelli

Philippe Lucarelli

Auto-generated profile, based on publicly available information

Philippe Lucarelli

Systems Biology Group, Life Sciences Research Unit, University of Luxembourg, Belvaux, Luxembourg

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
EAElham Alsahafi
Elham Alsahafi
KBKatheryn Begg
Katheryn Begg
IAIvano Amelio
Ivano Amelio
NRNina Raulf
Nina Raulf
PLPhilippe Lucarelli
Philippe Lucarelli
Mahvash TavassoliMahvash Tavassoli
Mahvash Tavassoli
Head and neck squamous cell carcinomas (HNSCCs) are an aggressive, genetically complex and difficult to treat group of cancers. In lieu of truly effective targeted therapies, surgery and radiotherapy represent the primary treatment options for most patients. But these treatments are associated with significant morbidity and a reduction in quality of life. Resistance to both radiotherapy and the only available targeted therapy, and subsequent relapse are common. Research has therefore focussed on identifying biomarkers to stratify patients into clinically meaningful groups and to develop more effective targeted therapies. However, as we are now discovering, the poor response to therapy and aggressive nature of HNSCCs is not only affected by the complex alterations in intracellular signalling pathways but is also heavily influenced by the behaviour of the extracellular microenvironment. The HNSCC tumour landscape is an environment permissive of these tumours’ aggressive nature, fostered by the actions of the immune system, the response to tumour hypoxia and the influence of the microbiome. Solving these challenges now rests on expanding our knowledge of these areas, in parallel with a greater understanding of the molecular biology of HNSCC subtypes. This update aims to build on our earlier 2014 review by bringing up to date our understanding of the molecular biology of HNSCCs and provide insights into areas of ongoing research and perspectives for the future.

1 June 2020 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
AMAnna S. Monzel
Anna S. Monzel
KHKathrin Hemmer
Kathrin Hemmer
TKTony Kaoma
Tony Kaoma
LSLisa M. Smits
Lisa M. Smits
SBSilvia Bolognin
Silvia Bolognin
JSJens Schwamborn
Jens Schwamborn
Brain organoids are highly complex multi-cellular tissue proxies, which have recently risen as novel tools to study neurodegenerative diseases such as Parkinson's disease (PD). However, with increasing complexity of the system, usage of quantitative tools becomes challenging. The primary objective of this study was to develop a neurotoxin-induced PD organoid model and to assess the neurotoxic effect on dopaminergic neurons using microscopy-based phenotyping in a high-content fashion. We describe a pipeline for a machine learning-based analytical method, allowing for detailed image-based cell profiling and toxicity prediction in brain organoids treated with the neurotoxic compound 6-hydroxydopamine (6-OHDA). We quantified features such as dopaminergic neuron count and neuronal complexity and built a machine learning classifier with the data to optimize data processing strategies and to discriminate between different treatment conditions. We validated the approach with high content imaging data from PD patient derived midbrain organoids. The here described model is a valuable tool for advanced in vitro PD modeling and to test putative neurotoxic compounds.

1 January 2018 in Cell Systems
Verified
Journal Article
Open access
PLPhilippe Lucarelli
Philippe Lucarelli
MSMarcel Schilling
Marcel Schilling
CKClemens Kreutz
Clemens Kreutz
AVArtyom Vlasov
Artyom Vlasov
MBMartin E. Boehm
Martin E. Boehm
UKUrsula Klingmüller
Ursula Klingmüller
Upon stimulation of cells with transforming growth factor β (TGF-β), Smad proteins form trimeric complexes and activate a broad spectrum of target genes. It remains unresolved which of the possible Smad complexes are formed in cellular contexts and how these contribute to gene expression. By combining quantitative mass spectrometry with a computational selection strategy, we predict and provide experimental evidence for the three most relevant Smad complexes in the mouse hepatoma cell line Hepa1-6. Utilizing dynamic pathway modeling, we specify the contribution of each Smad complex to the expression of representative Smad target genes, and show that these contributions are conserved in human hepatoma cell lines and primary hepatocytes. We predict, based on gene expression data of patient samples, increased amounts of Smad2/3/4 proteins and Smad2 phosphorylation as hallmarks of hepatocellular carcinoma and experimentally verify this prediction. Our findings demonstrate that modeling approaches can disentangle the complexity of transcription factor complex formation and its impact on gene expression.

1 October 2018 in European Journal of Cancer
Verified
Journal Article
Open access
NRN. Raulf
N. Raulf
PLP. Lucarelli
P. Lucarelli
STSelvam Thavaraj
Selvam Thavaraj
SBS. Brown
S. Brown
JVJ.M. Vicencio
J.M. Vicencio
Mahvash TavassoliMahvash Tavassoli
Mahvash Tavassoli
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer with approximately half a million cases diagnosed each year worldwide. HNSCC has a poor survival rate which has not improved for over 30 years. The molecular pathogenesis of HNSCCs remains largely unresolved; there is high prevalence of p53 mutations and EGFR overexpression; however, the contribution of these molecular changes to disease development and/or progression remains unknown. We have recently identified microRNA miR-196a to be highly overexpressed in HNSCC with poor prognosis. Oncogenic miR-196a directly targets Annexin A1 (ANXA1). Although increased ANXA1 expression levels have been associated with breast cancer development, its role in HNSCC is debatable and its functional contribution to HNSCC development remains unclear. ANXA1 mRNA and protein expression levels were determined by RNA Seq analysis and immunohistochemistry, respectively. Gain- and loss-of-function studies were performed to analyse the effects of ANXA1 modulation on cell proliferation, mechanism of activation of EGFR signalling as well as on exosome production and exosomal phospho-EGFR. ANXA1 was found to be downregulated in head and neck cancer tissues, both at mRNA and protein level. Its anti-proliferative effects were mediated through the intracellular form of the protein. Importantly, ANXA1 downregulation resulted in increased phosphorylation and activity of EGFR and its downstream PI3K-AKT signalling. Additionally, ANXA1 modulation affected exosome production and influenced the release of exosomal phospho-EGFR. ANXA1 acts as a tumour suppressor in HNSCC. It is involved in the regulation of EGFR activity and exosomal phospho-EGFR release and could be an important prognostic biomarker.

1 March 2012 in Biophysical Chemistry
Verified
Journal Article
Closed access
KWKatja Wegner
Katja Wegner
ABAnastasia Bachmann
Anastasia Bachmann
JSJan-Ulrich Schad
Jan-Ulrich Schad
PLPhilippe Lucarelli
Philippe Lucarelli
SSSven Sahle
Sven Sahle
UKUrsula Kummer
Ursula Kummer

9 October 2017 in Frontiers in Physiology
Verified
Journal Article
Open access
SSSvantje Sobotta
Svantje Sobotta
ARAndreas Raue
Andreas Raue
XHXiaoyun Huang
Xiaoyun Huang
JVJoep Vanlier
Joep Vanlier
AJAnja Jünger
Anja Jünger
UKUrsula Klingmüller
Ursula Klingmüller
IL-6 is a central mediator of the immediate induction of hepatic acute phase proteins (APP) in the liver during infection and after injury, but increased IL-6 activity has been associated with multiple pathological conditions. In hepatocytes, IL-6 activates JAK1-STAT3 signaling that induces the negative feedback regulator SOCS3 and expression of APPs. While different inhibitors of IL-6-induced JAK1-STAT3-signaling have been developed, understanding their precise impact on signaling dynamics requires a systems biology approach. Here we present a mathematical model of IL-6-induced JAK1-STAT3 signaling that quantitatively links physiological IL-6 concentrations to the dynamics of IL-6-induced signal transduction and expression of target genes in hepatocytes. The mathematical model consists of coupled ordinary differential equations (ODE) and the model parameters were estimated by a maximum likelihood approach, whereas identifiability of the dynamic model parameters was ensured by the Profile Likelihood. Using model simulations coupled with experimental validation we could optimize the long-term impact of the JAK-inhibitor Ruxolitinib, a therapeutic compound that is quickly metabolized. Model-predicted doses and timing of treatments helps to improve the reduction of inflammatory APP gene expression in primary mouse hepatocytes close to levels observed during regenerative conditions. The concept of improved efficacy of the inhibitor through multiple treatments at optimized time intervals was confirmed in primary human hepatocytes. Thus, combining quantitative data generation with mathematical modeling suggests that repetitive treatment with Ruxolitinib is required to effectively target excessive inflammatory responses without exceeding doses recommended by the clinical guidelines.